|
|
Post by barnstormer on Oct 22, 2017 7:42:25 GMT -5
Isn't is possible that Amphaster has already done some of the ground work for approval in China since the have a right to the distribution in China?
|
|
|
|
Post by barnstormer on Oct 15, 2017 7:33:11 GMT -5
I think 1,3 & 4 are probably accurate. I think Ken has a lot more confidence in Mike than Hakan & Matt so he feels safe with his investment.
|
|
|
|
Post by barnstormer on Oct 13, 2017 10:38:23 GMT -5
Sorry holdem, did't get all the way through your post.
|
|
|
|
Post by barnstormer on Oct 13, 2017 10:36:39 GMT -5
Amphaster is already operating in China, partners with Mannkind and has first right of refusal to distribute Afrezza in China. They may have already files.
|
|
|
|
Post by barnstormer on Sept 7, 2017 16:54:13 GMT -5
Pfizer failed inhaled insulin with Exhubra. If I were Urbanski I'd keep Pfizer off my resume too. Probably juiced his application. I'd say he wasn't Mike's man. Bring in some proven talent. Ray was an "Also Ran" .
|
|
|
|
Post by barnstormer on Aug 12, 2017 15:45:15 GMT -5
Seriously 2,900 shares is nothing and Ray hasn't delivered much so maybe he is moving on and being replaced by Mike by a real executive.
|
|
|
|
Post by barnstormer on Jul 22, 2017 14:38:28 GMT -5
So Exhubra is very present even though it is no longer available
|
|
|
|
Post by barnstormer on Jul 8, 2017 8:23:25 GMT -5
You do realize that Matt had never been a CEO and if you look accross many great companies CFO's rarely translate into CEO's. Great CEO's have a sales background in their resume. It takes a lot of talent to sell the comany's vision. Matt could barely speak on the earnings calls. Mike has no problem relating the company vision. I'll take Mike any day over a CFO that bungled important issues like delisting notification and warrant filing.
|
|
|
|
Post by barnstormer on Jul 4, 2017 9:09:45 GMT -5
Interesting that no one is speculating or talking about Locust Walk in the overall scheme of things. They have after all been engaged to seek new opportunities. New opportunites should bring in cash no?
|
|
|
|
Post by barnstormer on Jun 9, 2017 23:21:35 GMT -5
Please give the Amgen buyout a rest. It isn't in the cards for now or it would have already happened. Mannkind is taking all steps to make it on their own and no big stakeholders would accept a tender offer in line with the current market cap. Amgen or no other wise company is just going to throw in an offer at a huge premium.
|
|
|
|
Post by barnstormer on Jun 4, 2017 16:57:34 GMT -5
TYCOD is not sponsored by MNKD or at least not the TCOYD events in San Diego. Other insulin companies are sponsors. Edelman is a diabetic and Afrezza user
|
|
|
|
Post by barnstormer on May 15, 2017 16:18:32 GMT -5
I sent a copy of the postcard to Matt asking his thoughts on the card and the lack of Q&A I am hearing at the sh meeting. He usually answers so we will see what he has to say.
|
|
|
|
Post by barnstormer on May 15, 2017 15:51:09 GMT -5
|
|
|
|
Post by barnstormer on Apr 22, 2017 9:25:35 GMT -5
Sorry, but how can anyone say this BOD has been successful. The Chairman is 79 years old and has done nothing to help this company. A BOD shake up will not ensure the failure, they are a big part of the failure so far. It's time to bring in some fresh blood with a better grasp of today's BP environment. This group has proven they are naive to the forces working to suppress MNKD, Afrezza. Al Mann was a great inventor, but he seeded the BOD with members that are not from the industry. I for one don't want to keep this failed status-quo while the company burns through cash. Management's past plans have failed. TASE offering failed to raise enough cash. RS took only a couple of weeks to drop share price back under $1 and only encouraged the shorts to continue. If there isn't real change soon Matt will be the last out the door turning out the lights
|
|
|
|
Post by barnstormer on Apr 19, 2017 13:48:25 GMT -5
|
|
